Thaddeus Allen, PhD
Chief Executive Officer
Thaddeus founded Tradewind in 2017 with the vision of translating research discoveries into novel therapeutics for cancer patients. He has served in leadership and business development roles with life science start-ups, led drug discovery teams, and managed patent portfolios. In addition to other fundraising, Thaddeus brought Tradewind through the Y Combinator accelerator program in Mountain View, California. With more than 20 years of cancer research experience, Thaddeus has authored 35 publications. He earned his PhD in Cellular and Molecular Biology from the University of Toronto, and trained in the laboratory of Nobel Laureate, J. Michael Bishop at the University of California, San Francisco.
Chief Business Officer
Melanie brings extensive experience in corporate development, finance and capital markets. She has a background in corporate finance advisory for public and private life science companies and in the funding of multiple small- and medium-sized growth enterprises with risk capital. More recently, Melanie held M&A and strategic partnership roles with tech-enabled consulting service and digital health technology providers. She holds an MBA from the Wharton School of the University of Pennsylvania.
Director, Scientific Advisory Board
Ron is a Professor of Medicine at University of Pittsburgh Medical Center (UPMC), Director of the Ovarian Cancer Center of Excellence, and Co-Director of the Women's Cancer Research Center at Magee-Womens Research Institute. A pioneer in the field of ovarian cancer stem cells, he has received multiple honors including a Clinical Investigator Award from the Damon Runyon Cancer Research Foundation and the National Institutes of Health, New Innovator Directors Award. Ron received an MD from Cornell University and a PhD from the Rockefeller University.
Copyright © 2021 Tradewind BioScience - All Rights Reserved.